Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
March 14 Product: Madrigals Rezdiffra Indication: MASH In one of the years most highly anticipated FDA decisions, Madrigal Pharmaceuticals won approval Thursday for resmetiromhenceforth to be known as Rezdiffraas the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH), formerly noncirrhotic non-alcoholic steatohepatitis (NASH)
Weight Loss Results Injectable GLP-1 medications remain among the most effective weight-loss treatments available
e - g , Treatment of DIO mice with once daily s.c
One study had people on doses as high as 2,000 micrograms with no side effects
However, negotiated pricing mechanisms may help contain long-term costs
US$ 21.91
US$ 29.61
US$ 24.20
US$ 29.70
US$ 25.45
